The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib study of avelumab and novel AXL inhibitor avb-S6-500 in patients with metastatic urothelial carcinoma (mUC).
 
Abhishek Tripathi
Honoraria - Urology times
Consulting or Advisory Role - Deka Biosciences; EMD Serono; Exelixis; Foundation Medicine; Genzyme; Pfizer; Seagen
Research Funding - Aravive (Inst); Bayer (Inst); Bayer (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst); EMD Serono (Inst); Exact Sciences (Inst); Pfizer (Inst); WindMIL (Inst)
 
Melissa Clingerman
No Relationships to Disclose
 
Riza Celine Fabreo
No Relationships to Disclose
 
Adanma Ayanambakkam
No Relationships to Disclose
 
Brian Cross
No Relationships to Disclose
 
Kelly Lynn Stratton
Honoraria - Bayer; Dendreon (Inst); Janssen; Johnson & Johnson/Janssen; Merck; MJH Life Sciences; Oakstone Publishing; Oakstone Publishing (Inst); Sun Pharma; Urology times
Consulting or Advisory Role - AMRO Pharma (Inst); Bayer (Inst); Bayer (Inst); Clovis Oncology (Inst); Dendreon (Inst); Large Urology Group Practice Association (Inst); Myriad Genetics (Inst); Sanofi (Inst)
Speakers' Bureau - Arkansas Urology; Bayer
Research Funding - Advantage Pharmaceuticals (Inst); Alliance Foundation Trials (Inst); Anchiano (Inst); Astellas ENACT CTA (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Dendreon (Inst); EMD Serono (Inst); EMD Serono (Inst); Ferring (Inst); Genentech (Inst); Myovant Sciences (Inst); Myriad Genetics (Inst); Myriad Genetics (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Roche/Genentech (Inst); RTOG (Inst); TARIS Biomedical (Inst); TARIS Biomedical (Inst)
Travel, Accommodations, Expenses - Dendreon; Dendreon (Inst); Myriad Genetics
 
Michael Cookson
Honoraria - AstraZeneca/MedImmune; Clovis Oncology; FerGene; Merck; Myovant Sciences
Consulting or Advisory Role - Astellas Pharma; Bayer; Ferring; Genomic Health; Janssen Biotech; MDxHealth; Merck; Myovant Sciences; Precision Biopsy; TesoRX Pharmaceuticals
 
Sumanta K. Pal
Consulting or Advisory Role - F. Hoffmann LaRoche; F. Hoffmann LaRoche; Roche
Research Funding - Eisai (Inst); Exelixis (Inst); Genentech (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Genentech; Seagen
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Foundation Medicine; Foundation Medicine; Genentech; Gilead Sciences; Janssen Oncology; Lilly; Lilly; Lilly; Medivation/Astellas; MEI Pharma; Merck; Nektar; Novartis; Pfizer; Pfizer; Pharmacyclics; Seagen
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)